Fairmount Funds Management LLC bought $25.0M of Cogent Biosciences (COGT)
Executed Jul 10 2025, disclosed Jul 14 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 14 2025), the stock returned +0.0% (delay-adjusted); from the execution session (Jul 10 2025), +3.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Fairmount Funds Management LLC (Director) filed 8 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 4 priced purchase filings, the average 21-session return was -7.3% from execution and -3.8% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.
Healthcare · Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→7,000,000 sh × $34.66
Exec Mar 31
Filed Mar 31 · 5:30 PM ET COGTSALE Cogent Biosciences, Inc. $127.4M
3,500,000 sh × $36.40
Exec Jan 22
Filed Jan 22 · 5:30 PM ET